{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-001174","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.166169+00:00","generated_at":"2026-06-11T12:04:03.428121+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcturus' JV ARCALIS awarded $115M in Japanese government grants; achieves $17.5M CSL flu milestone","bullets":["ARCALIS, Arcturus' 49%-owned joint venture, receives $115M in two grants to build a cGMP mRNA factory in Minamisoma, Japan.","LUNAR-FLU program achieves $17.5M development milestone from CSL Seqirus; funds used for flu program development activities.","The factory will support cGMP production of mRNA drug substance and drug product for Arcturus' STARR mRNA vaccines.","CSL Seqirus is exclusive global licensee for mRNA vaccines against COVID-19, flu, and three other respiratory diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-001174","json":"https://secwatch.observer/filing/0001193805-23-001174.json","markdown":"https://secwatch.observer/filing/0001193805-23-001174.md","text":"https://secwatch.observer/filing/0001193805-23-001174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/0001193805-23-001174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/e618874_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:04:03.428121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4e810078565984931d679e013b476628843f986","claim":"Arcturus Therapeutics Holdings Inc. entered into CSL Collaboration Agreement with Seqirus, Inc., a part of CSL Seqirus (effective 2022-12-08).","evidence_excerpt":"the Company entered into the CSL Collaboration Agreement with CSL Seqirus for the global exclusive rights to research, develop, manufacture and commercialize Arcturus’ self-amplifying mRNA vaccines against COVID-19, influenza and three other respiratory infectious diseases with nonexclusive rights to pandemic pathogens","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/0001193805-23-001174-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Seqirus, Inc., a part of CSL Seqirus"},{"label":"Effective","value":"2022-12-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}